Miguel Ángel Hernández Pérez

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Evaluation of Kappa Index as a Tool in the Diagnosis of Multiple Sclerosis: Implementation in Routine Screening Procedure

Carmen T. Díaz, Silvia de las Heras Flórez, Mercedes Carretero Pérez et al. · Frontiers in Neurology · 2021 · 33 citations · Full text

PD–PID controller for delayed systems with two unstable poles: a frequency domain approach

David Fernando Novella Rodríguez, Basilio del Muro‐Cuéllar, Juan Francisco Márquez‐Rubio et al. · International Journal of Control · 2017 · 25 citations

Nonlinear Control, Time Delay Size, Delayed Systems +10

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

B. Singer, Douglas L. Arnold, Jelena Drulović et al. · Multiple Sclerosis Journal · 2023 · 22 citations · Full text

Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective

José Meca-Lallana, Jorge Mauriño, Miguel Ángel Hernández Pérez et al. · Neurology and Therapy · 2020 · 18 citations · Full text